Bupivacaine/meloxicam - Heron Therapeutics

Drug Profile

Bupivacaine/meloxicam - Heron Therapeutics

Alternative Names: Bupivacaine/meloxicam extended release; HTX-002/HTX-009; HTX-009/HTX-002; HTX-011; HTX-011A; HTX-011B; Meloxicam/bupivacaine; Meloxicam/bupivacaine extended release

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heron Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pipecolic acids; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 08 Jan 2018 Heron Therapeutics completes enrolment in its phase III EPOCH-1 and EPOCH-2 trials for Postoperative pain in USA (NCT03237481) (NCT03295721)
  • 06 Nov 2017 Heron Therapeutics has patent protection for bupivacaine/meloxicam for prevention of Postoperative pain in USA
  • 26 Oct 2017 Bupivacaine/meloxicam receives Fast Track designation for Postoperative pain [Infiltration] (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top